Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Has Average Price Target of $19.40 According to Brokerages

Theravance Biopharma, Inc. (NASDAQ:TBPH) has earned a consensus rating of “Hold” from the eight brokerages that are presently covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold rating. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $19.40.

TBPH has been the topic of several research analyst reports. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 7th. HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $15.00 to $17.00 in a report on Tuesday, July 7th. BTIG Research reissued a “neutral” rating on shares of Theravance Biopharma in a research note on Thursday. JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Finally, Weiss Ratings raised shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, August 17th.

Insiders Place Their Bets

In other Theravance Biopharma news, major shareholder Eli Samaha sold 273,871 shares of Theravance Biopharma stock in a transaction on Monday, June 29th. The shares were sold at an average price of $17.23, for a total value of $4,718,797.33. Following the completion of the sale, the insider directly owned 9,237,279 shares of the company’s stock, valued at approximately $159,158,317.17. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $17.03, for a total transaction of $226,737.42. Following the transaction, the senior vice president owned 213,476 shares in the company, valued at $3,635,496.28. This represents a 5.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 350,011 shares of company stock worth $6,016,830 in the last quarter. 7.65% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd raised its stake in Theravance Biopharma by 51.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,133 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 1,408 shares during the period. Globeflex Capital L P acquired a new stake in Theravance Biopharma in the first quarter valued at approximately $171,000. Allspring Global Investments Holdings LLC acquired a new stake in Theravance Biopharma in the first quarter valued at approximately $171,000. Cannon Global Investment Management LLC bought a new stake in shares of Theravance Biopharma during the first quarter valued at approximately $260,000. Finally, Financiere des Professionnels Fonds d investissement inc. bought a new stake in shares of Theravance Biopharma during the first quarter valued at approximately $268,000. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Up 0.1%

Shares of NASDAQ TBPH opened at $17.05 on Tuesday. The company has a market capitalization of $884.98 million, a PE ratio of 16.88 and a beta of 0.25. Theravance Biopharma has a twelve month low of $13.08 and a twelve month high of $21.03. The firm has a fifty day simple moving average of $16.97 and a 200 day simple moving average of $16.48.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The firm had revenue of $20.73 million for the quarter, compared to the consensus estimate of $22.49 million. As a group, equities analysts expect that Theravance Biopharma will post 1.56 earnings per share for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.